CEO: Patrick Banks

Advent Contact: Shahzad Malik/Kaasim Mahmood

European specialty pharmaceutical company with a portfolio of urology products

SEP acquired and licensed several products for the European specialty urology and urogynaecology market. SEP sold a number of brands including Mitem®/Mitocin for bladder cancer and Regurin® for overactive bladder through its own sales force at the time of its acquisition.

Advent founded SEP in 2006. SEP was acquired by Juno/ Aspire Pharmaceuticals in 2016.